Prognostic Impact of Clostridium butyricum MIYAIRI (CBM588) in Combination With Pembrolizumab for Advanced Urothelial Carcinoma: A Retrospective Cohort Study

Prognostic Impact of Clostridium butyricum MIYAIRI (CBM588) in Combination With Pembrolizumab for Advanced Urothelial Carcinoma: A Retrospective Cohort Study

ABSTRACT Background Combining the probiotic product CBM588 with immune checkpoint inhibitors (ICIs) has shown improved prognosis in several cancers. Pembrolizumab alone as a second‐line treatment for urothelial cancer (UC) extends prognosis by only 3 months. Aims This is a retrospective study that e...

Full description

Saved in:
Bibliographic Details
Main Authors: Junya Arima, Hirofumi Yoshino, Shuichi Tatarano, Akihiko Mitsuke, Yoichi Osako, Takashi Sakaguchi, Ryosuke Matsushita, Satoru Inoguchi, Yasutoshi Yamada, Hideki Enokida
Format: Article
Language:English
Published: Wiley 2025-08-01
Series:Cancer Reports
Subjects:
CBM588
pembrolizumab
probiotics
urothelial cancer
Online Access:https://doi.org/10.1002/cnr2.70308
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cnr2.70308

Similar Items